'Obesity Not Just Cosmetic': Eli Lilly Ready For Weight-Loss Drug Mounjaro Launch In India | Interview
The prevalence of obesity in India was lower than in other countries but now it's increasing, Rachel Batterham, senior vice ...
Novo Nordisk's Innovation Supports a Wide Moat and GLP-1 Market Growth
We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...
Zacks.com on MSN13h
NVO Q4 Earnings Beat Estimates, GLP-1 Drugs Boost Sales, Stock Up
Novo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...
corporate-adviser.com13h
Waiting for weight-loss jabs
Weight-loss jabs such as Ozempic are being hailed as a potential breakthrough in the fight against obesity. Demand, fuelled ...
Hydreight Technologies Expands Telehealth Offerings with Launch of NAD+ Therapy on VSDHOne Platform
NAD+ IonToPatch – Utilizing iontophoresis, a non-invasive transdermal drug delivery system that uses a voltage gradient to increase skin permeability, allowing for effective NAD+ absorption. The latex ...
Hosted on MSN20h
Found vs Calibrate: Which Is Better For Prescription Weight Loss?
Fitness and nutrition gurus like to make weight loss sound easy. But in reality, it’s often incredibly tough to incorporate ...